Evaluating the reproducibility of research in obstetrics and gynecology.


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 08 06 2021
revised: 19 11 2021
accepted: 11 12 2021
pubmed: 27 12 2021
medline: 3 2 2022
entrez: 26 12 2021
Statut: ppublish

Résumé

Reproducibility is a core tenet of scientific research. A reproducible study is one where the results can be recreated by using the same methodology and materials as the original researchers. Unfortunately, reproducibility is not a standard to which the majority of research is currently adherent. Our cross-sectional survey evaluated 300 trials in the field of Obstetrics and Gynecology. Our primary objective was to identify nine indicators of reproducibility and transparency. These indicators include availability of data, analysis scripts, pre-registration information, study protocols, funding source, conflict of interest statements and whether or not the study was available via Open Access. Of the 300 trials in our sample, 208 contained empirical data that could be assessed for reproducibility. None of the trials in our sample provided a link to their protocols or provided a statement on availability of materials. None were replication studies. Just 10.58% provided a statement regarding their data availability, while only 5.82% provided a statement on preregistration. 25.85% failed to report the presence or absence of conflicts of interest and 54.08% did not state the origin of their funding. In the studies we examined, research in the field of Obstetrics and Gynecology is not consistently reproducible and frequently lacks conflict of interest disclosure. Consequences of this could be far-reaching and include increased research waste, widespread acceptance of misleading results and erroneous conclusions guiding clinical decision-making.

Identifiants

pubmed: 34954422
pii: S0301-2115(21)01020-4
doi: 10.1016/j.ejogrb.2021.12.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

24-29

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Shelby Rauh (S)

Oklahoma State University Center for Health Sciences, Tulsa, OK, United States. Electronic address: shelby.rauh@okstate.edu.

Aaron Bowers (A)

Oklahoma State University Center for Health Sciences, Tulsa, OK, United States.

Drayton Rorah (D)

Kansas City University of Medicine and Biosciences, Joplin, MO, United States.

Daniel Tritz (D)

Oklahoma State University Center for Health Sciences, Tulsa, OK, United States.

Heather Pate (H)

Department of Obstetrics and Gynecology, Oklahoma State University Medical Center, Tulsa, OK, United States.

Lance Frye (L)

Department of Obstetrics and Gynecology, Oklahoma State University Medical Center, Tulsa, OK, United States.

Matt Vassar (M)

Oklahoma State University Center for Health Sciences, Tulsa, OK, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH